1,351
Participants
Start Date
July 19, 2019
Primary Completion Date
November 30, 2020
Study Completion Date
November 30, 2020
PCV-free liquid formulation of GSK's oral live attenuated HRV vaccine
2 doses administered orally at Day 1 and at Month 1 or Month 2, according to the immunization schedule for RV vaccine administration in participating countries.
Lyophilized formulation of GSK's oral live attenuated HRV vaccine
2 doses administered orally at Day 1 and at Month 1 or Month 2, according to the immunization schedule for RV vaccine administration in participating countries.
GSK Investigational Site, Taipei
GSK Investigational Site, Taipei
GSK Investigational Site, Changhua
GSK Investigational Site, Syracuse
GSK Investigational Site, Frederick
GSK Investigational Site, Charlottesville
GSK Investigational Site, Eskişehir
GSK Investigational Site, Birmingham
GSK Investigational Site, Izmir
GSK Investigational Site, Kayseri
GSK Investigational Site, Louisville
GSK Investigational Site, Fairfield
GSK Investigational Site, Cincinnati
GSK Investigational Site, Bingham Farms
GSK Investigational Site, Lincoln
GSK Investigational Site, Lincoln
GSK Investigational Site, Lincoln
GSK Investigational Site, Colorado Springs
GSK Investigational Site, Kaohsiung City
GSK Investigational Site, Draper
GSK Investigational Site, Orem
GSK Investigational Site, South Jordan
GSK Investigational Site, Murray
GSK Investigational Site, Corvallis
GSK Investigational Site, Fall River
GSK Investigational Site, East Orange
GSK Investigational Site, Calgary
GSK Investigational Site, Surrey
GSK Investigational Site, Halifax
GSK Investigational Site, Truro
GSK Investigational Site, Brampton
GSK Investigational Site, London
GSK Investigational Site, Sarnia
GSK Investigational Site, Montreal
GSK Investigational Site, Québec
GSK Investigational Site, Pokfulam
GSK Investigational Site, Shatin
Lead Sponsor
GlaxoSmithKline
INDUSTRY